A randomized, double-blind, placebo controlled, multicenter study of subcutaneous AIN457 to demonstrate efficacy at Week 12 compared to placebo and etanercept and to assess the safety, tolerability and long-term efficacy up to one year in subjects with moderate to severe chronic plaque-type psoriasis.
Zielgerichtet
